Clinical Trial Detail

NCT ID NCT03088176
Title Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors West Cancer Center
Indications

melanoma

Therapies

Dabrafenib + Talimogene laherparepvec + Trametinib

Age Groups: adult senior

Additional content available in CKB BOOST